vs
弗雷斯特研究公司（FORR）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是弗雷斯特研究公司的1.4倍（$140.6M vs $101.1M），VERACYTE, INC.净利率更高（29.3% vs -33.5%，领先62.8%），VERACYTE, INC.同比增速更快（18.5% vs -6.5%），VERACYTE, INC.自由现金流更多（$48.8M vs $-4.3M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 0.5%）
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
FORR vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.4倍
$101.1M
营收增速更快
VCYT
高出25.0%
-6.5%
净利率更高
VCYT
高出62.8%
-33.5%
自由现金流更多
VCYT
多$53.1M
$-4.3M
两年增速更快
VCYT
近两年复合增速
0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $101.1M | $140.6M |
| 净利润 | $-33.9M | $41.1M |
| 毛利率 | 56.7% | 72.5% |
| 营业利润率 | -36.6% | 26.4% |
| 净利率 | -33.5% | 29.3% |
| 营收同比 | -6.5% | 18.5% |
| 净利润同比 | -7941.4% | 704.8% |
| 每股收益（稀释后） | $-1.75 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORRVCYT
| Q4 25 | $101.1M | $140.6M | ||
| Q3 25 | $94.3M | $131.9M | ||
| Q2 25 | $111.7M | $130.2M | ||
| Q1 25 | $89.9M | $114.5M | ||
| Q4 24 | $108.0M | $118.6M | ||
| Q3 24 | $102.5M | $115.9M | ||
| Q2 24 | $121.8M | $114.4M | ||
| Q1 24 | $100.1M | $96.8M |
净利润FORRVCYT
| Q4 25 | $-33.9M | $41.1M | ||
| Q3 25 | $-2.1M | $19.1M | ||
| Q2 25 | $3.9M | $-980.0K | ||
| Q1 25 | $-87.3M | $7.0M | ||
| Q4 24 | $432.0K | $5.1M | ||
| Q3 24 | $-5.8M | $15.2M | ||
| Q2 24 | $6.3M | $5.7M | ||
| Q1 24 | $-6.7M | $-1.9M |
毛利率FORRVCYT
| Q4 25 | 56.7% | 72.5% | ||
| Q3 25 | 60.0% | 69.2% | ||
| Q2 25 | 55.5% | 69.0% | ||
| Q1 25 | 55.9% | 69.5% | ||
| Q4 24 | 58.8% | 66.4% | ||
| Q3 24 | 60.5% | 68.2% | ||
| Q2 24 | 57.3% | 68.1% | ||
| Q1 24 | 54.9% | 64.5% |
营业利润率FORRVCYT
| Q4 25 | -36.6% | 26.4% | ||
| Q3 25 | 4.7% | 17.4% | ||
| Q2 25 | 6.2% | -4.0% | ||
| Q1 25 | -97.5% | 2.5% | ||
| Q4 24 | -0.5% | 3.5% | ||
| Q3 24 | -0.7% | 10.4% | ||
| Q2 24 | 9.3% | 4.0% | ||
| Q1 24 | -9.3% | -4.8% |
净利率FORRVCYT
| Q4 25 | -33.5% | 29.3% | ||
| Q3 25 | -2.3% | 14.5% | ||
| Q2 25 | 3.5% | -0.8% | ||
| Q1 25 | -97.1% | 6.2% | ||
| Q4 24 | 0.4% | 4.3% | ||
| Q3 24 | -5.7% | 13.1% | ||
| Q2 24 | 5.2% | 5.0% | ||
| Q1 24 | -6.7% | -1.9% |
每股收益（稀释后）FORRVCYT
| Q4 25 | $-1.75 | $0.50 | ||
| Q3 25 | $-0.11 | $0.24 | ||
| Q2 25 | $0.20 | $-0.01 | ||
| Q1 25 | $-4.62 | $0.09 | ||
| Q4 24 | $0.02 | $0.07 | ||
| Q3 24 | $-0.30 | $0.19 | ||
| Q2 24 | $0.33 | $0.07 | ||
| Q1 24 | $-0.35 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.3M | $362.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $126.5M | $1.3B |
| 总资产 | $404.0M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FORRVCYT
| Q4 25 | $63.3M | $362.6M | ||
| Q3 25 | $65.1M | $315.6M | ||
| Q2 25 | $67.8M | $219.5M | ||
| Q1 25 | $75.6M | $186.1M | ||
| Q4 24 | $56.1M | $239.1M | ||
| Q3 24 | $62.8M | $274.1M | ||
| Q2 24 | $58.9M | $235.9M | ||
| Q1 24 | $61.4M | $209.2M |
股东权益FORRVCYT
| Q4 25 | $126.5M | $1.3B | ||
| Q3 25 | $157.7M | $1.3B | ||
| Q2 25 | $159.5M | $1.2B | ||
| Q1 25 | $147.4M | $1.2B | ||
| Q4 24 | $229.5M | $1.2B | ||
| Q3 24 | $234.3M | $1.2B | ||
| Q2 24 | $237.1M | $1.1B | ||
| Q1 24 | $230.9M | $1.1B |
总资产FORRVCYT
| Q4 25 | $404.0M | $1.4B | ||
| Q3 25 | $414.2M | $1.4B | ||
| Q2 25 | $436.0M | $1.3B | ||
| Q1 25 | $439.8M | $1.3B | ||
| Q4 24 | $503.9M | $1.3B | ||
| Q3 24 | $505.3M | $1.3B | ||
| Q2 24 | $524.2M | $1.2B | ||
| Q1 24 | $555.7M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.2M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $-4.3M | $48.8M |
| 自由现金流率自由现金流/营收 | -4.2% | 34.7% |
| 资本支出强度资本支出/营收 | 1.1% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $18.1M | $126.6M |
8季度趋势，按日历期对齐
经营现金流FORRVCYT
| Q4 25 | $-3.2M | $52.6M | ||
| Q3 25 | $1.2M | $44.8M | ||
| Q2 25 | $-3.6M | $33.6M | ||
| Q1 25 | $26.7M | $5.4M | ||
| Q4 24 | $-1.8M | $24.5M | ||
| Q3 24 | $264.0K | $30.0M | ||
| Q2 24 | $-2.9M | $29.6M | ||
| Q1 24 | $611.0K | $-9.0M |
自由现金流FORRVCYT
| Q4 25 | $-4.3M | $48.8M | ||
| Q3 25 | $524.0K | $42.0M | ||
| Q2 25 | $-4.2M | $32.3M | ||
| Q1 25 | $26.1M | $3.5M | ||
| Q4 24 | $-2.5M | $20.4M | ||
| Q3 24 | $-223.0K | $27.7M | ||
| Q2 24 | $-3.7M | $26.8M | ||
| Q1 24 | $-815.0K | $-11.1M |
自由现金流率FORRVCYT
| Q4 25 | -4.2% | 34.7% | ||
| Q3 25 | 0.6% | 31.8% | ||
| Q2 25 | -3.8% | 24.8% | ||
| Q1 25 | 29.0% | 3.1% | ||
| Q4 24 | -2.3% | 17.2% | ||
| Q3 24 | -0.2% | 23.9% | ||
| Q2 24 | -3.1% | 23.4% | ||
| Q1 24 | -0.8% | -11.5% |
资本支出强度FORRVCYT
| Q4 25 | 1.1% | 2.7% | ||
| Q3 25 | 0.7% | 2.1% | ||
| Q2 25 | 0.5% | 1.0% | ||
| Q1 25 | 0.7% | 1.6% | ||
| Q4 24 | 0.6% | 3.5% | ||
| Q3 24 | 0.5% | 1.9% | ||
| Q2 24 | 0.7% | 2.4% | ||
| Q1 24 | 1.4% | 2.2% |
现金转化率FORRVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | -0.93× | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | -4.24× | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | -0.46× | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
